Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.

Zhu L, Li H, Chan P, Eley T, Gandhi Y, Bifano M, Osawa M, Ueno T, Hughes E, AbuTarif M, Bertz R, Garimella T.

Infect Dis Ther. 2018 Jun;7(2):261-275. doi: 10.1007/s40121-018-0197-y. Epub 2018 Mar 27.

2.

Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.

Chan P, Li H, Zhu L, Bifano M, Eley T, Osawa M, Ueno T, Hughes E, Bertz R, Garimella T, AbuTarif M.

Clin Pharmacokinet. 2017 Oct;56(10):1173-1183. doi: 10.1007/s40262-016-0504-2.

PMID:
28066880
3.

Cellular Telephone Dialing Influences Kinematic and Spatiotemporal Gait Parameters in Healthy Adults.

Seymour KM, Higginson CI, DeGoede KM, Bifano MK, Orr R, Higginson JS.

J Mot Behav. 2016 Nov-Dec;48(6):535-541. Epub 2016 Jun 24.

PMID:
27340890
4.

A Review of Daclatasvir Drug-Drug Interactions.

Garimella T, You X, Wang R, Huang SP, Kandoussi H, Bifano M, Bertz R, Eley T.

Adv Ther. 2016 Nov;33(11):1867-1884. Epub 2016 Sep 23. Review.

5.

Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations.

Chan P, Mould DR, Tarif MA, Reynolds L, LaCreta F, Bertz R, Bifano M.

Clin Pharmacokinet. 2016 Dec;55(12):1559-1572.

PMID:
27319000
6.

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.

Zeuzem S, Hézode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourlière M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S; LEAGUE-1 Study Team.

J Hepatol. 2016 Feb;64(2):292-300. doi: 10.1016/j.jhep.2015.09.024. Epub 2015 Oct 8.

PMID:
26453968
7.

Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.

Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M, Bruce RD, Hwang C, Bertz R, Bifano M.

Antimicrob Agents Chemother. 2015 Sep;59(9):5503-10. doi: 10.1128/AAC.00478-15. Epub 2015 Jun 29.

8.

An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects.

Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ.

Clin Drug Investig. 2015 May;35(5):281-9. doi: 10.1007/s40261-015-0279-5.

9.

Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.

Shiozaki T, Ueno T, Nagashima H, Yamahira N, Hiraoka M, Eley T, Bifano M, Bertz RJ.

Int J Clin Pharmacol Ther. 2015 Apr;53(4):292-302. doi: 10.5414/CP202186.

PMID:
25740262
10.

Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment.

Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, Marbury TC, Alcorn H, Bertz R, Bifano M.

Antivir Ther. 2015;20(5):535-43. doi: 10.3851/IMP2941. Epub 2015 Feb 5.

PMID:
25654812
11.

Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone.

Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, Demicco M, Bruce D, Hwang C, Bertz R, Bifano M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19628. doi: 10.7448/IAS.17.4.19628. eCollection 2014.

12.

The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.

Eley T, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, Gardiner D, Grasela DM, Bertz R, Bifano M.

Clin Drug Investig. 2014 Sep;34(9):661-71. doi: 10.1007/s40261-014-0219-9.

PMID:
25117173
13.

Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.

Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R.

Antivir Ther. 2014;19(5):511-9. doi: 10.3851/IMP2718. Epub 2013 Dec 17.

PMID:
24343001
14.

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.

Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, Velinova-Donga M, Kandoussi H, Sevinsky H, Bertz R.

Antivir Ther. 2013;18(7):931-40. doi: 10.3851/IMP2674. Epub 2013 Aug 20.

PMID:
23963204
15.

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.

Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT.

Am J Transplant. 2013 Jun;13(6):1601-5. doi: 10.1111/ajt.12209. Epub 2013 Apr 17.

16.

Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay.

Jiang H, Zeng J, Li W, Bifano M, Gu H, Titsch C, Easter J, Burrell R, Kandoussi H, Aubry AF, Arnold ME.

Anal Chem. 2012 Nov 20;84(22):10031-7. doi: 10.1021/ac3024558. Epub 2012 Nov 6.

PMID:
23106420
17.

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.

Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M.

Liver Transpl. 2012 Sep;18(9):1053-9. doi: 10.1002/lt.23482.

18.

A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.

Jiang H, Zeng J, Kandoussi H, Liu Y, Wang X, Bifano M, Cojocaru L, Ryan J, Arnold ME.

J Chromatogr A. 2012 Jul 6;1245:117-21. doi: 10.1016/j.chroma.2012.05.028. Epub 2012 May 14.

PMID:
22640838
19.

Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.

Gu H, Wang J, Aubry AF, Jiang H, Zeng J, Easter J, Wang JS, Dockens R, Bifano M, Burrell R, Arnold ME.

Anal Chem. 2012 Jun 5;84(11):4844-50. doi: 10.1021/ac300442v. Epub 2012 May 10.

PMID:
22540405
20.

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, DeMicco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-Talavera JC, Grasela DM.

Hepatology. 2011 Dec;54(6):1956-65. doi: 10.1002/hep.24609.

PMID:
21837752
21.

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

Fridell RA, Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M.

Hepatology. 2011 Dec;54(6):1924-35. doi: 10.1002/hep.24594.

PMID:
21809362
22.

Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis.

Goodenough AK, Onorato JM, Ouyang Z, Chang S, Rodrigues AD, Kasichayanula S, Huang SP, Turley W, Burrell R, Bifano M, Jemal M, LaCreta F, Tymiak A, Wang-Iverson D.

Chem Res Toxicol. 2011 Sep 19;24(9):1575-85. doi: 10.1021/tx2001898. Epub 2011 Jul 21.

PMID:
21728364
23.

Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients.

Yoshitsugu H, Sakurai T, Ishikawa H, Roy A, Bifano M, Pfister M, Seriu T, Hiraoka M.

Diagn Microbiol Infect Dis. 2011 May;70(1):91-100. doi: 10.1016/j.diagmicrobio.2010.12.009.

PMID:
21513847
24.

Application of elastic wave dispersion relations to estimate thermal properties of nanoscale wires and tubes of varying wall thickness and diameter.

Bifano MF, Kaul PB, Prakash V.

Nanotechnology. 2010 Jun 11;21(23):235704. doi: 10.1088/0957-4484/21/23/235704. Epub 2010 May 17.

PMID:
20472943
25.

Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients.

Zhu M, Bifano M, Xu X, Wang Y, LaCreta F, Grasela D, Pfister M.

Antimicrob Agents Chemother. 2008 Aug;52(8):2836-41. doi: 10.1128/AAC.01366-07. Epub 2008 Apr 7.

26.

Absence of a pharmacokinetic interaction between entecavir and adefovir.

Bifano M, Yan JH, Smith RA, Zhang D, Grasela DM, LaCreta F.

J Clin Pharmacol. 2007 Oct;47(10):1327-34. Epub 2007 Aug 3.

PMID:
17675455
27.

Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.

Yan JH, Bifano M, Olsen S, Smith RA, Zhang D, Grasela DM, LaCreta F.

J Clin Pharmacol. 2006 Nov;46(11):1250-8.

PMID:
17050790
28.

Scleritodermin A, a cytotoxic cyclic peptide from the lithistid sponge Scleritoderma nodosum.

Schmidt EW, Raventos-Suarez C, Bifano M, Menendez AT, Fairchild CR, Faulkner DJ.

J Nat Prod. 2004 Mar;67(3):475-8.

PMID:
15043437
29.

Synthesis, structure proof, and biological activity of epothilone cyclopropanes.

Johnson J, Kim SH, Bifano M, DiMarco J, Fairchild C, Gougoutas J, Lee F, Long B, Tokarski J, Vite G.

Org Lett. 2000 Jun 1;2(11):1537-40.

PMID:
10841473
30.

Generation of replication-competent hepatitis B virus nucleocapsids in insect cells.

Seifer M, Hamatake R, Bifano M, Standring DN.

J Virol. 1998 Apr;72(4):2765-76.

32.

Establishment of an in vitro assay to characterize hepatitis C virus NS3-4A protease trans-processing activity.

Hamatake R, Wang HG, Butcher JA, Bifano M, Clark G, Hernandez D, Zhang S, Racela J, Standring D, Colonno R.

Intervirology. 1996;39(4):249-58.

PMID:
9078466
33.

Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein.

Sheaffer AK, Hurlburt WW, Stevens JT, Bifano M, Hamatake RK, Colonno RJ, Tenney DJ.

Virus Res. 1995 Oct;38(2-3):305-14.

PMID:
8578868
34.

Sequence-dependent primer synthesis by the herpes simplex virus helicase-primase complex.

Tenney DJ, Sheaffer AK, Hurlburt WW, Bifano M, Hamatake RK.

J Biol Chem. 1995 Apr 21;270(16):9129-36.

35.
36.

The herpes simplex virus type 1 DNA polymerase accessory protein, UL42, contains a functional protease-resistant domain.

Hamatake RK, Bifano M, Tenney DJ, Hurlburt WW, Cordingley MG.

J Gen Virol. 1993 Oct;74 ( Pt 10):2181-9.

PMID:
8409941
37.

Deletions of the carboxy terminus of herpes simplex virus type 1 UL42 define a conserved amino-terminal functional domain.

Tenney DJ, Hurlburt WW, Bifano M, Stevens JT, Micheletti PA, Hamatake RK, Cordingley MG.

J Virol. 1993 Apr;67(4):1959-66.

38.

Mutations in the C terminus of herpes simplex virus type 1 DNA polymerase can affect binding and stimulation by its accessory protein UL42 without affecting basal polymerase activity.

Tenney DJ, Micheletti PA, Stevens JT, Hamatake RK, Matthews JT, Sanchez AR, Hurlburt WW, Bifano M, Cordingley MG.

J Virol. 1993 Jan;67(1):543-7.

39.

Hypothalamic-pituitary somatotropic function in prepubertal hypothyroid rats: effect of growth hormone replacement therapy.

De Gennaro Colonna V, Bertola G, Coco CB, Bifano M, Cocchi D, Maggi A, Müller EE.

Proc Soc Exp Biol Med. 1991 Apr;196(4):432-7.

PMID:
1672566
40.

Changes in the hypothalamic-pituitary somatotropic function of infant hypothyroid rats.

De Gennaro Colonna V, Bertola G, Coco CB, Bifano M, Cocchi D, Maggi A, Müller EE.

Proc Soc Exp Biol Med. 1990 Mar;193(3):214-9.

PMID:
1968255

Supplemental Content

Loading ...
Support Center